Size and donor disparity influence IOP GAT

Article

Graft size and donor-recipient disparity influence IOP measured with the Goldmann applanation tonometer (IOP GAT) after penetrating keratoplasty (PKP).

Larger grafts and greater donor-recipient disparity are factors influencing IOP measured with the Goldmann applanation tonometer (IOP GAT) after penetrating keratoplasty (PKP), according to a paper in the journal Cornea.

Dr S. Feizi et al., Ophthalmic Research Centre, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, conducted a cross-sectional study on 34 eyes of 34 keratoconus patients who had experienced penetrating keratoplasty (PKP).

At least six months postoperatively corneal hysteresis (CH), corneal resistance factor (CRF) and cornea-compensated intraocular pressure were measured. The independent t-test was used to compare two groups of donor-recipient disparity. Multivariate regression analysis was employed to assess the correlation of donor trephine size and central graft thickness (CGT) with the ocular response analyzer (ORA). The factors influencing IOP measured with the IOP GAT after PKP were identified using multiple regression analysis.

The findings revealed that mean CGT, CH and CRF were 564.7 ± 36.9 μm, 10.1 ± 2.1 mmHg, and 10.0 ± 2.3 mmHg, respectively. CH and CRF were positively correlated with donor trephine size and CGT, with significant values being observed in the 0.5 mm disparity group, opposed to the 0.25 mm disparity group.

The journal abstract can be found here

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.